Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study to Assess the Efficacy and Safety of Luveris® (Lutropin Alfa) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Premenopausal woman, aged 35 to 42 years wanting to become pregnant~* Subjects with FSH baseline plasma levels less than or equal to 10 IU/L (Day 2-5 of the cycle) and with LH and E2 levels within the normal limits of the local laboratory~* Subjects having regular spontaneous menstrual cycle lasting 25-35 days~* Subjects with infertility that is susceptible to treatment with IVF/ICSI~* Subjects to be included in a COS protocol with r-hFSH and GnRHant~* Subjects with partner's sperm suitable for IVF/ICSI according to local laboratory, unless sperm donor is to be used~* Subjects with both ovaries~* Subjects with uterine cavity capable of sustaining the implantation of embryo or carrying a pregnancy~* Subjects with normal pap smear (papanicolaou) 6 months prior to be included in the study (signature of informed consent)~* Subjects with body mass index (BMI) less than (\<) 30 at the beginning of ovarian stimulation~* Subjects with confirmed absence of pregnancy with the beta-hCG test (urine or blood) before starting the administration of r-hFSH~* Subjects willing to adjust to the protocol for the entire duration of the study~* Subjects who have given informed consent prior to any study-related procedure that is not part of normal medical care~Exclusion Criteria:~* Subjects or her partner with known positivity for human immunodeficiency virus (HIV) or Hepatitis-B /Hepatitis-C virus (HBV/HCV)~* Subjects with any systemic illnesses of clinical significance, hypothalamus and pituitary tumors; cancer of ovaries, uterus or breast; hormonal anomalies and/or medical, biochemical, hematological illnesses that, according to the investigator, could interfere with the treatment with gonadotropins~* Subjects with more than 2 previous ART cycles~* Subjects who have cancelled two previous ART cycles~* Subjects with frozen embryos from previous ART cycles~* Subjects with non-specific gynecological bleeding~* Subjects with ovaries that are polycystic, increased in size or with cysts of unknown etiology~* Subjects with any contraindication for becoming pregnant and/or carrying pregnancy to term~* Subjects with known allergy to gonadotropin preparations or any of the excipients~* Subjects with drug dependence or history of drug or alcohol abuse in the previous 5 years~* Subjects who have previously entered into this study or simultaneous participation in another clinical drug trial with drugs~* Subjects who are unwilling to or not being able to adjust to the study protocol

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: 42 Years
- Healthy Volunteers: f

Study Arms:
- r-hLH + r-hFSH (Type: EXPERIMENTAL): None
- r-hFSH (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues